Asia-Pacific Bladder Cancer Market Growth, Analysis Report, Share, Trends and Overview 2022-2028
Asia-Pacific
bladder cancer market is estimated to grow at a CAGR of around 9.7% during the
forecast period. The growing number of smokers in Asian economies is one of the
major factors attributing to the increasing number of bladder cancer patients.
The number of smokers is increasing substantially in the adult population of
the region due to the changing lifestyle and shifting habits towards smoking
and tobacco consumption. Other factors that are considered as the significant
cause of bladder cancer include radiation exposure, intake, or exposure to
hazardous chemicals, aging, and others. Aging is considered as the major
factors leading to bladder cancer due to the weakening of immune cells against
cancer tissues in the bladder. Countries of Asia-Pacific such as Japan and
China are reported to the aging population rapidly. Therefore, Asia-Pacific is
comparatively more prone to bladder cancer as compared to other regions.
A full report of Asia-Pacific Bladder Cancer
Market is available at: https://www.omrglobal.com/industry-reports/asia-pacific-bladder-cancer-market
Asia-Pacific
bladder cancer market is segmented into cancer type, diagnosis, and treatment.
Based on cancer type, the market is segmented into transitional cell bladder
cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and
other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the
market is segmented into cystoscopy, biopsy, urinalysis, urine cytology,
intravenous pyelogram (IVP), and others. Based on treatment, the market is
segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and
other treatment which include targeted therapy. The chemotherapy is highly
adopted as it kills cancer cells that are spread to other parts of the body,
far from its primary tumor.
To learn more about this report request a sample
copy @ https://www.omrglobal.com/request-sample/asia-pacific-bladder-cancer-market
The
companies which are contributing to the growth of the Asia-Pacific bladder
cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly
& Co., GlaxoSmithKline PLC, Sysmex Corp., and Pfizer, Inc. The market
players are considerably contributing to the market growth by the adoption of
various strategies including new product launches, mergers, and acquisitions,
collaborations with government, funding to the start-ups, and technological
advancements to stay competitive in the market.
Asia-Pacific Bladder Cancer Market- Segmentation
By
Cancer type
·
Transitional Cell Bladder Cancer/ Urothelial
Carcinoma
·
Squamous Cell Bladder Cancer
·
Adenocarcinoma
·
Other Rare Types (Sarcomas, Carcinoma in Situ)
By
Diagnosis Method
·
Cystoscopy
·
Biopsy
·
Urinalysis
·
Urine Cytology
·
Intravenous Pyelogram (Ivp)
·
Other
By
Therapy
·
Chemotherapy
·
Immunotherapy
·
Radiation Therapy
·
Surgery
·
Other
Asia-Pacific Bladder Cancer Market– Segment by
Region
·
China
·
Japan
·
India
·
Rest of
Asia-Pacific
Company Profiles
·
Astellas Pharma
Inc.
·
AstraZeneca PLC
·
Bayer AG
·
Bristol-Myers
Squibb Co.
·
Eli Lilly and Co.
·
F. Hoffmann-La
Roche Ltd.
·
GlaxoSmithKline Plc
·
Johnson &
Johnson Services, Inc.
·
Merck KGaA
·
Pfizer Inc.
·
Sysmex Corp.
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more
than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and
after purchasing your report.
About Orion Market Research
Orion
Market Research (OMR) is a market research and consulting company known for its
crisp and concise reports. The company is equipped with an experienced team of
analysts and consultants. OMR offers quality syndicated research reports,
customized research reports, consulting and other research-based services.
Media Contact:
Contact
Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no:
+91 780-304-0404
Company
Name: Orion Market Research
0 Comments